Trial Profile
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2016
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ULDS
- Sponsors AstraZeneca
- 25 Jun 2010 New trial record